Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate
  • Clinical Data

Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

BioSpace

If Biogen has shown that tau can impact cognition, Denali's technology--validated with an FDA approval in Hunter syndrome--could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

pharminent May 15, 2026

BioSpace

If Biogen has shown that tau can impact cognition, Denali’s technology–validated with an FDA approval in Hunter syndrome–could ensure the medicine gets where it needs to be for the greatest therapeuti

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Genmab drops 2 antibody assets, including another ProfoundBio ADC
Next: ECO 2026: tirzepatide shows potential for T1D treatment

Related Stories

  • Clinical Data

Parsortix study shows promise for ADC target detection

pharminent August 3, 2026
  • Clinical Data

Novo setback casts doubt on a new way to treat heart disease

pharminent July 31, 2026
  • Clinical Data

Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study

pharminent July 28, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.